The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The companies will work with investigators to share the results with the scientific community
The company is already marketing the 4 mg and 10 mg strengths
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Subscribe To Our Newsletter & Stay Updated
